GenEdit, Inc. today announced achievement of the first milestone from the multiyear collaboration and license agreement with Genentech, a member of the Roche Group. The companies are employing GenEdit’s NanoGalaxy platform to discover and develop hydrophilic nanoparticles (HNPs) that can be used to develop nucleic acid-based medicines for autoimmune indications.
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules